UCB stock carries a EUR 285 consensus target after HY sales growth

Published on 09/25/2026 at 12:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UCB stock carried a EUR 285.00 average target on September 24, 2026, against a EUR 213.40 quote. BIMZELX sales reached EUR 1.52 billion in HY 2026.

Moderner Biopharma-Forschungscampus mit Glasgebäuden und Laborpersonal in Brüssel bei Tageslicht — UCB S.A. mit ISIN BE0003739530 zeigt modernen Forschungscampus in Brüssel mit Laborpersonal in Glasgebäuden, Illustration mit AI erstellt.

UCB stock (ISIN BE0003739530) was trading at EUR 213.40 on Euronext Brussels on September 24, 2026, at 11:45 a.m. BST, up 0.85 percent from the prior close of EUR 211.60. The average analyst target stood at EUR 285.00, putting the target 33.55 percent above the quoted price.

Analysts see a higher valuation

MarketScreener reported on September 11, 2026, that the consensus covered 20 analysts and assigned UCB a BUY rating, with an average target of EUR 285.00. The quoted EUR 213.40 price was 10.65 percent below its January 1, 2026 level, despite a 2.21 percent gain over five trading days.

The valuation gap is therefore substantial but not a standalone signal. The market price and the analyst target describe different dates and purposes, while the year-to-date decline shows that the stock has not yet recovered its earlier losses.

Drug sales shift toward BIMZELX

UCB's HY 2026 product mix shows why BIMZELX has become central to the company story. The investor page lists BIMZELX sales of EUR 1.52 billion, compared with EUR 954 million for CIMZIA and EUR 327 million for BRIVIACT in the same period, according to UCB.

BIMZELX sales were EUR 566 million higher than CIMZIA sales in HY 2026. The investor page also lists BIMZELX peak-sales guidance above EUR 7 billion, giving the leading growth product a larger long-term commercial ambition than its current half-year sales base.

Brussels listing anchors the quote

PR Newswire identifies UCB as a global biopharmaceutical company and confirms its Euronext Brussels listing under the symbol UCB. The company focuses on medicines for severe diseases affecting the immune system and central nervous system.

UCB stock stays below its target

UCB stock was trading at EUR 213.40 on Euronext Brussels on September 24, 2026, with a session change of 0.85 percent. The next valuation checkpoint is whether product growth, led by BIMZELX, can narrow the gap between the market price and the EUR 285.00 consensus target.